Navamedic

Regulatory Filings • May 5, 2025

Navamedic ASA launches Eroxon® in Denmark

Navamedic ASA launches Eroxon® in Denmark

Oslo, 05 May 2025 - Navamedic ASA (OSE: NAVA), a Nordic pharma company and

trusted supplier of high-quality prescription, consumer health, and hospital

products to hospitals and pharmacies, today announced it has launched Eroxon®, a

clinically proven over-the-counter topical treatment for the treatment of

erectile dysfunction in men, in Denmark.

The product launch marks the fourth launch of Eroxon® in the Nordics since

Navamedic introduced the product to the Norwegian market in February 2024. As

part of Navamedic's Consumer Health area, Eroxon® will be available to Danish

consumers, without a prescription, across pharmacies.

Ahead of the launch, Navamedic carried out a study through YouGov1[1]. According

to the study, more than 500,000 Danish men over the age of 18 have experienced

erectile problems, and 23 per cent of Danish men have erectile dysfunction (ED).

The study also revealed that four out of ten men who have experienced ED feel it

has impacted either their confidence or quality of life.

"These results are not surprising and confirm how widespread erectile problems

are. It is still taboo to experience erectile problems, and it has a significant

psychological aspect, which we can see with 39 per cent of men where it has

affected their self-confidence or quality of life.  We want to change that, and

we need to have the courage to talk about men's sexual health," says Fredrik

Hultberg, Country Manager at Navamedic.

Including the launch of Eroxon® in Denmark, the product is now available to

consumers in Norway, Sweden and Finland. Eroxon® offers a range of features

which differentiates it from other forms of treatments for erectile dysfunction.

It is an effective and fast-acting gel which typically helps men get an erection

within ten minutes of application. It has a good safety profile due to its local

effect with no systemic absorption. Eroxon® has been approved as a treatment for

erectile dysfunction in the EU and the US.

"We are confident that Eroxon® will be a success in Denmark. Until now, Danish

pharmacies have lacked a non-prescription product to treat ED. Based on the

recent study, Danish men are looking for a treatment that can quickly provide an

erection, and we believe Eroxon® meets that desire as it works within 10

minutes," added Fredrik Hultberg, Country Manager at Navamedic.

1] About the study

The survey was conducted by the research institute YouGov. A total of 1,526 CAWI

interviews were conducted with Danish men and women aged 18-89 years from March

26 to April 1, 2025.

For further information, please contact:

Kathrine Gamborg Andreassen, CEO, Navamedic

Mobile: +47 951 78 680

E-mail: kathrine@navamedic.com

Lars Hjarrand, CFO, Navamedic

Mobile: +47 917 62 842

E-mail: lars.hjarrand@navamedic.com

About Navamedic

Navamedic ASA is a Nordic pharmaceutical company dedicated to enhancing people's

quality of life by being a reliable supplier of high-quality prescription,

consumer health, and hospital products to hospitals and pharmacies. Our growing

product portfolio has been carefully selected to meet current public health

concerns, such as obesity, Parkinson's disease, antibiotics and metabolism, to

empower people to live healthier and more fulfilling lives. What sets us apart

is our deep-rooted commitment to understanding the needs and requirements of the

countries where we are present. Our local insight and competence enable us to

understand the specific needs of each country where we operate and ultimately to

gain market access. This makes us a preferred partner for international

companies expanding their footprint across the Nordics and Benelux regions,

through either in-licensing or out-licensing. Navamedic has been listed on the

Oslo Stock Exchange since 2006 (ticker: NAVA) and is headquartered in Oslo,

Norway.

For more information, please visit Navamedic.com.

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Trading Act.